A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI.
Washington-A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI, according to UCLA researchers.
Based on its performance, the revised CCI may be useful for counseling men about management of early-stage prostate cancer, said first author Timothy Daskivich, MD, a urology resident at UCLA's David Geffen School of Medicine working with Mark S. Litwin, MD, MPH, and colleagues.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.